001     166579
005     20240917140552.0
024 7 _ |a 10.2337/db19-0659
|2 doi
024 7 _ |a pmid:33239449
|2 pmid
024 7 _ |a 0012-1797
|2 ISSN
024 7 _ |a 1939-327X
|2 ISSN
024 7 _ |a altmetric:95011416
|2 altmetric
037 _ _ |a DKFZ-2020-03022
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Chen, Jessy
|b 0
245 _ _ |a CaM Kinase II-δ is Required for Diabetic Hyperglycemia and Retinopathy but not Nephropathy.
260 _ _ |a Alexandria, Va
|c 2021
|b Assoc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726574730_16365
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Feb;70(2):616-626
520 _ _ |a Type 2 diabetes has become a pandemic and leads to late diabetic complications of organs including kidney and eye. Lowering hyperglycemia is the typical therapeutic goal in clinical medicine. However, hyperglycemia may only be a symptom of diabetes but not the sole cause of late diabetic complications, Instead, other diabetes-related alterations could be causative. Here, we studied the role of CaM Kinase II δ (CaMKIIδ) that is known to be activated through diabetic metabolism. CaMKIIδ is expressed ubiquitously and might therefore affect several different organ systems. We crossed diabetic leptin receptor mutant mice to mice lacking CaMKIIδ globally. Remarkably, CaMKIIδ-deficient diabetic mice did not develop hyperglycemia. As potential underlying mechanisms, we provide evidence for improved insulin sensing with increased glucose transport into skeletal muscle but also reduced hepatic glucose production. Despite normoglycemia, CaMKIIδ-deficient diabetic mice developed the full picture of diabetic nephropathy but diabetic retinopathy was prevented. We also unmasked a retina-specific gene expression signature that might contribute to CaMKII-dependent retinal diabetic complications. These data challenge the clinical concept of normalizing hyperglycemia in diabetes as a causative treatment strategy for late diabetic complications and call for a more detailed analysis of intracellular metabolic signals in different diabetic organs.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Fleming, Thomas
|b 1
700 1 _ |a Katz, Sylvia
|b 2
700 1 _ |a Dewenter, Matthias
|b 3
700 1 _ |a Hofmann, Kai
|b 4
700 1 _ |a Saadatmand, Alireza
|b 5
700 1 _ |a Kronlage, Mariya
|b 6
700 1 _ |a Werner, Moritz P
|b 7
700 1 _ |a Pokrandt, Bianca
|b 8
700 1 _ |a Schreiter, Friederike
|b 9
700 1 _ |a Lin, Jihong
|b 10
700 1 _ |a Katz, Daniel
|b 11
700 1 _ |a Morgenstern, Jakob
|b 12
700 1 _ |a Elwakiel, Ahmed
|b 13
700 1 _ |a Sinn, Peter
|b 14
700 1 _ |a Gröne, Hermann-Josef
|0 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
|b 15
700 1 _ |a Hammes, Hans-Peter
|b 16
700 1 _ |a Nawroth, Peter P
|b 17
700 1 _ |a Isermann, Berend
|b 18
700 1 _ |a Sticht, Carsten
|b 19
700 1 _ |a Brügger, Britta
|b 20
700 1 _ |a Katus, Hugo A
|b 21
700 1 _ |a Hagenmueller, Marco
|b 22
700 1 _ |a Backs, Johannes
|b 23
773 _ _ |a 10.2337/db19-0659
|g p. db190659 -
|0 PERI:(DE-600)1501252-9
|n 2
|p 616-626
|t Diabetes
|v 70
|y 2021
|x 1939-327X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:166579
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DIABETES : 2018
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-08-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-08-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-08-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b DIABETES : 2018
|d 2020-08-29
920 1 _ |0 I:(DE-He78)G130-20160331
|k G130
|l Zelluläre und Molekulare Pathologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G130-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21